echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The novel coronavirus pneumonia treatment plan for the three edition of the sixth edition of the fourth edition medicine and fast reading society

    The novel coronavirus pneumonia treatment plan for the three edition of the sixth edition of the fourth edition medicine and fast reading society

    • Last Update: 2020-02-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [February 19, 2020 / medical information list] Inspur health has completed a round of financing of 100 million yuan; Haichen pharmaceutical's application for registration of apixaban tablets has been accepted; five prime new drug combined with opdivo pancreatic cancer phase 2 clinical failure; keytruda's 6-week drug administration plan has been rejected by FDA Daily fresh medicine news, speed reading club and you pay attention to! As of 24:00 on February 18, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 57805 confirmed cases (including 11977 severe cases), 14376 cured and discharged cases, 2004 dead cases, 74185 confirmed cases and 5248 suspected cases There were 574418 close contacts and 135881 close contacts still under medical observation (official website of the health care Commission) The novel coronavirus novel coronavirus pneumonia treatment plan was launched on 19 th, the national health and Health Committee (trial version sixth) The new version of the diagnostic and therapeutic plan has made relevant adjustments to the transmission route, clinical manifestation, diagnostic criteria, clinical classification, differential diagnosis, case finding, report and treatment of the new coronavirus (official website of the health care Commission) On Tuesday, Inspur Health announced the completion of round a financing of 100 million yuan, and Galaxy Securities, Yinji investment and qingkong Jinxin blue fund participated in this round of investment It is understood that this round of financing will help tide to introduce excellent talents, further promote innovation of big data platform and artificial intelligence products and services, and accelerate the construction and operation of regional big data (billion euro) Recently, Imara announced that it plans to raise US $86 million through IPO to further promote the clinical development of its first candidate drug for the treatment of sickle cell anemia It is reported that the company was launched in 2016 by cydan, an orphan drug accelerator (chuangjianhui) The second indication of apatinib, a new class 1 drug of Hengrui, was put on the market Monday, according to the CDE website It is reported that its second indication is second-line treatment of liver cancer Apatinib is the second approved class 1 new drug of Hengrui, and it is the King brand product of Hengrui (CPHI Pharma online) On the 18th, Hengrui pharmaceutical registered to launch a phase III clinical study of fluzopali or fluzopali combined with apatinib mesylate compared with placebo in the maintenance treatment of advanced ovarian cancer after first-line platinum containing chemotherapy It is reported that this randomized, double-blind, parallel controlled phase III clinical trial plans to group 680 patients with advanced ovarian cancer (medicine cube) According to the announcement issued by Sihuan pharmaceutical on the 18th, the group's cabalastine heavy Tartrate Capsules and levetiracetam tablets have obtained the drug production approval issued by the State Food and drug administration, while midazolam oral and buccal mucosal solution has obtained the drug registration approval (Fourth Ring pharmaceutical announcement) On February 19, Beida pharmaceutical announced that the bpi-28592 clinical trial application applied by the company has been accepted by the State Food and Drug Administration for the treatment of solid tumor patients (Bada pharmaceutical announcement) On August 18, Haichen pharmaceutical announced that it had recently received the notice of acceptance of drug registration of apixaban tablets According to Article 32 of the administrative license law of the people's Republic of China, the State Food and drug administration examined the drug registration application of the above drugs and decided to accept it (announcement of Haichen pharmaceutical) Japan's Ministry of health, labor and welfare has granted research drug rg6042 orphan drug qualification to treat Huntington's disease, Roche Holding Japanese pharmaceutical company sinopharma announced recently It is reported that rg6042 is an antisense RNA drug, which has been proved to reduce the production of mutant Huntington protein, the root cause of HD (Biovalley) Tuesday, Roche announced that the U.S FDA has accepted tecentriq's application for a license to supplement biological agents as a first-line single drug therapy for advanced non squamous and squamous non-small cell lung cancer patients with high PD-L1 expression and no EGFR or ALK mutations The U.S FDA also grants the application priority review qualification, and will make the approval decision before June 19, 2020 (yaomingkant) On Tuesday, CDE official website showed that GSK's application for the listing of dotiravilamivudine in China was proposed to be included in the priority review according to the scope of priority review (1) 3 drugs with obvious treatment advantages It is reported that dovato was developed by Viiv healthcare under GSK, which was approved by FDA on April 8, 2019 and EU on July 3, 2019 (medicine cube) The clinical application of byl719 filed by Novartis in China was accepted by CDE on the 19th The new drug, which was approved by FDA on May 24, 2019, is called piqray, and has gained sales of 116 million US dollars in the past seven months since its launch (medicine cube) On August 18, five prime therapeutics announced that the combination of cabiralizumab and opdivo, which were carried out in cooperation with Bristol Myers Squibb, failed to reach its primary end point in the treatment of advanced pancreatic cancer stage 2 The share price of five prime biotechnology fell about 10% after the news (Sina Medical News) MSD announced on the 18th that the FDA has issued a complete response letter to its six applications for approval of supplementary biological products (SBLA) The six SBLA samples sought to update the administration frequency of keytruda, and were included in the 6-week administration plan, specifically: 400mg intravenous infusion every 6 weeks for at least 30 minutes, for a variety of treatment indications (Sina Medical News) Pfizer recently announced that the European Commission has approved vyndaqel It is reported that the drug is a 61 mg oral capsule once a day, which is used to treat adult patients with wild-type or hereditary PTH (Biovalley) Novo Nordisk recently announced that esperoct has been marketed in the United States for use in adults and children with hemophilia A It is reported that esperoct was approved by FDA in February 2019, but due to the third-party intellectual property agreement, Novo Nordisk is unable to launch esperoct in the U.S market before 2020 (yaozhi.com) Recently, the mid-term analysis of the phase II clinical trial of classical lung IB published at the 2020 clinical immunooncology Symposium showed that pepinemab combined with Merck / Pfizer anti PD-L1 therapy bavencio in the treatment of advanced non-small cell lung cancer showed antitumor activity and good tolerance (Biovalley)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.